Dual antiplatelet therapy and clinical outcomes after coronary drug-eluting stent implantation in patients on hemodialysis

Yung Tai Chen, Hung Ta Chen, Chien Yi Hsu, Pei Wen Chao, Shu Chen Kuo, Shuo Ming Ou, Chia Jen Shih

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Background and objectives We aimed to investigate the benefits and risks of dual antiplatelet therapy (DAPT) after coronary drug-eluting stent (DES) implantation in patients undergoing hemodialysis. Design, setting, participants, & measurements A nested case-control analysis of patients on hemodialysis after receipt of DES and DAPT treatment was conducted using data from Taiwan’s National Health Insurance Research Database for the period 2007–2011. Cases of myocardial infarction or death within 1 year after DES implantation were matched one-to-one with control patients. Odds ratios were calculated to compare DAPT continuation with discontinuation. Additionally, a propensity score–adjusted 6-month landmark cohort analysis was also conducted to evaluate the long-term benefits and risks of prolonged (>6 months) compared with ≤6 months of DAPT use. The primary outcomes were death and myocardial infarction. The secondary outcomes were ischemic stroke, revascularization, and major bleeding. Results In the nested case-control analysis, patients who continued DAPT had a lower rate of death or myocardial infarction within 1 year after receipt of a DES (adjusted odds ratio, 0.54; 95% confidence interval, 0.36 to 0.81; P=0.003), whereas this association became statistically nonsignificant when compared with patients who discontinued DAPT for the period between 6 and 12 months after receipt of a DES (adjusted odds ratio, 1.51; 95% confidence interval, 0.75 to 3.04). In the propensity score–adjusted cohort analysis, >6 months of DAPT use was not associated with different primary or secondary outcomes than shorter-term use. Conclusions Our findings support that the clinical effectiveness of extended DAPT in a hemodialysis population may be tempered after 6 months post-DES implantation.

Original languageEnglish
Pages (from-to)262-271
Number of pages10
JournalClinical Journal of the American Society of Nephrology
Volume12
Issue number2
DOIs
Publication statusPublished - 2017

Fingerprint

Drug-Eluting Stents
Renal Dialysis
Therapeutics
Odds Ratio
Myocardial Infarction
Cohort Studies
Confidence Intervals
National Health Programs
Stroke
Databases
Hemorrhage
Mortality

Keywords

  • 2’-deoxythymidylyl-(3’-5’)-2’-deoxyadenosine
  • Cohort
  • Coronary artery disease
  • Drug-eluting stents
  • Epidemiology and outcomes
  • Hemodialysis
  • Hemorrhage
  • Humans
  • Myocardial infarction
  • National health programs
  • Odds ratio
  • Propensity score
  • Renal dialysis
  • Risk assessment
  • Stroke
  • Studies
  • Taiwan
  • Treatment outcome

ASJC Scopus subject areas

  • Epidemiology
  • Critical Care and Intensive Care Medicine
  • Nephrology
  • Transplantation

Cite this

Dual antiplatelet therapy and clinical outcomes after coronary drug-eluting stent implantation in patients on hemodialysis. / Chen, Yung Tai; Chen, Hung Ta; Hsu, Chien Yi; Chao, Pei Wen; Kuo, Shu Chen; Ou, Shuo Ming; Shih, Chia Jen.

In: Clinical Journal of the American Society of Nephrology, Vol. 12, No. 2, 2017, p. 262-271.

Research output: Contribution to journalArticle

@article{d71100d3a35e4f4c87251e14e2b300d8,
title = "Dual antiplatelet therapy and clinical outcomes after coronary drug-eluting stent implantation in patients on hemodialysis",
abstract = "Background and objectives We aimed to investigate the benefits and risks of dual antiplatelet therapy (DAPT) after coronary drug-eluting stent (DES) implantation in patients undergoing hemodialysis. Design, setting, participants, & measurements A nested case-control analysis of patients on hemodialysis after receipt of DES and DAPT treatment was conducted using data from Taiwan’s National Health Insurance Research Database for the period 2007–2011. Cases of myocardial infarction or death within 1 year after DES implantation were matched one-to-one with control patients. Odds ratios were calculated to compare DAPT continuation with discontinuation. Additionally, a propensity score–adjusted 6-month landmark cohort analysis was also conducted to evaluate the long-term benefits and risks of prolonged (>6 months) compared with ≤6 months of DAPT use. The primary outcomes were death and myocardial infarction. The secondary outcomes were ischemic stroke, revascularization, and major bleeding. Results In the nested case-control analysis, patients who continued DAPT had a lower rate of death or myocardial infarction within 1 year after receipt of a DES (adjusted odds ratio, 0.54; 95{\%} confidence interval, 0.36 to 0.81; P=0.003), whereas this association became statistically nonsignificant when compared with patients who discontinued DAPT for the period between 6 and 12 months after receipt of a DES (adjusted odds ratio, 1.51; 95{\%} confidence interval, 0.75 to 3.04). In the propensity score–adjusted cohort analysis, >6 months of DAPT use was not associated with different primary or secondary outcomes than shorter-term use. Conclusions Our findings support that the clinical effectiveness of extended DAPT in a hemodialysis population may be tempered after 6 months post-DES implantation.",
keywords = "2’-deoxythymidylyl-(3’-5’)-2’-deoxyadenosine, Cohort, Coronary artery disease, Drug-eluting stents, Epidemiology and outcomes, Hemodialysis, Hemorrhage, Humans, Myocardial infarction, National health programs, Odds ratio, Propensity score, Renal dialysis, Risk assessment, Stroke, Studies, Taiwan, Treatment outcome",
author = "Chen, {Yung Tai} and Chen, {Hung Ta} and Hsu, {Chien Yi} and Chao, {Pei Wen} and Kuo, {Shu Chen} and Ou, {Shuo Ming} and Shih, {Chia Jen}",
year = "2017",
doi = "10.2215/CJN.04430416",
language = "English",
volume = "12",
pages = "262--271",
journal = "Clinical journal of the American Society of Nephrology : CJASN",
issn = "1555-9041",
publisher = "American Society of Nephrology",
number = "2",

}

TY - JOUR

T1 - Dual antiplatelet therapy and clinical outcomes after coronary drug-eluting stent implantation in patients on hemodialysis

AU - Chen, Yung Tai

AU - Chen, Hung Ta

AU - Hsu, Chien Yi

AU - Chao, Pei Wen

AU - Kuo, Shu Chen

AU - Ou, Shuo Ming

AU - Shih, Chia Jen

PY - 2017

Y1 - 2017

N2 - Background and objectives We aimed to investigate the benefits and risks of dual antiplatelet therapy (DAPT) after coronary drug-eluting stent (DES) implantation in patients undergoing hemodialysis. Design, setting, participants, & measurements A nested case-control analysis of patients on hemodialysis after receipt of DES and DAPT treatment was conducted using data from Taiwan’s National Health Insurance Research Database for the period 2007–2011. Cases of myocardial infarction or death within 1 year after DES implantation were matched one-to-one with control patients. Odds ratios were calculated to compare DAPT continuation with discontinuation. Additionally, a propensity score–adjusted 6-month landmark cohort analysis was also conducted to evaluate the long-term benefits and risks of prolonged (>6 months) compared with ≤6 months of DAPT use. The primary outcomes were death and myocardial infarction. The secondary outcomes were ischemic stroke, revascularization, and major bleeding. Results In the nested case-control analysis, patients who continued DAPT had a lower rate of death or myocardial infarction within 1 year after receipt of a DES (adjusted odds ratio, 0.54; 95% confidence interval, 0.36 to 0.81; P=0.003), whereas this association became statistically nonsignificant when compared with patients who discontinued DAPT for the period between 6 and 12 months after receipt of a DES (adjusted odds ratio, 1.51; 95% confidence interval, 0.75 to 3.04). In the propensity score–adjusted cohort analysis, >6 months of DAPT use was not associated with different primary or secondary outcomes than shorter-term use. Conclusions Our findings support that the clinical effectiveness of extended DAPT in a hemodialysis population may be tempered after 6 months post-DES implantation.

AB - Background and objectives We aimed to investigate the benefits and risks of dual antiplatelet therapy (DAPT) after coronary drug-eluting stent (DES) implantation in patients undergoing hemodialysis. Design, setting, participants, & measurements A nested case-control analysis of patients on hemodialysis after receipt of DES and DAPT treatment was conducted using data from Taiwan’s National Health Insurance Research Database for the period 2007–2011. Cases of myocardial infarction or death within 1 year after DES implantation were matched one-to-one with control patients. Odds ratios were calculated to compare DAPT continuation with discontinuation. Additionally, a propensity score–adjusted 6-month landmark cohort analysis was also conducted to evaluate the long-term benefits and risks of prolonged (>6 months) compared with ≤6 months of DAPT use. The primary outcomes were death and myocardial infarction. The secondary outcomes were ischemic stroke, revascularization, and major bleeding. Results In the nested case-control analysis, patients who continued DAPT had a lower rate of death or myocardial infarction within 1 year after receipt of a DES (adjusted odds ratio, 0.54; 95% confidence interval, 0.36 to 0.81; P=0.003), whereas this association became statistically nonsignificant when compared with patients who discontinued DAPT for the period between 6 and 12 months after receipt of a DES (adjusted odds ratio, 1.51; 95% confidence interval, 0.75 to 3.04). In the propensity score–adjusted cohort analysis, >6 months of DAPT use was not associated with different primary or secondary outcomes than shorter-term use. Conclusions Our findings support that the clinical effectiveness of extended DAPT in a hemodialysis population may be tempered after 6 months post-DES implantation.

KW - 2’-deoxythymidylyl-(3’-5’)-2’-deoxyadenosine

KW - Cohort

KW - Coronary artery disease

KW - Drug-eluting stents

KW - Epidemiology and outcomes

KW - Hemodialysis

KW - Hemorrhage

KW - Humans

KW - Myocardial infarction

KW - National health programs

KW - Odds ratio

KW - Propensity score

KW - Renal dialysis

KW - Risk assessment

KW - Stroke

KW - Studies

KW - Taiwan

KW - Treatment outcome

UR - http://www.scopus.com/inward/record.url?scp=85021626610&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021626610&partnerID=8YFLogxK

U2 - 10.2215/CJN.04430416

DO - 10.2215/CJN.04430416

M3 - Article

AN - SCOPUS:85021626610

VL - 12

SP - 262

EP - 271

JO - Clinical journal of the American Society of Nephrology : CJASN

JF - Clinical journal of the American Society of Nephrology : CJASN

SN - 1555-9041

IS - 2

ER -